Literature DB >> 23247805

Effect of ARHI on lung cancer cell proliferation, apoptosis and invasion in vitro.

Xiaohong Wu1, Li Liang, Liangliang Dong, Zhe Yu, Xiaoqing Fu.   

Abstract

The purposes of this study were to elucidate the effects of ARHI (aplysia ras homolog I) on several biological features of lung cancer cells, including growth, proliferation and invasion, to collect experimental evidence for the future biological treatment of human lung cancer. The eukaryotic expression vector, pcDNA3.1-ARHI, was constructed and transfected into the human lung cancer cell line SK-MES-1. The biological properties of the resulting ARHI-expressing lung cancer cell line were evaluated using methyl thiazolyl tetrazolium assay, flow cytometry, and a Transwell invasion assay. Additionally, the influence of ARHI on the gene expression levels of cyclin D1, p27(KIP1), death-associated protein kinase 1 (DAPK1), and matrix metalloproteinases1/2 (MMP-1/2) was determined. Compared to the non-transfected SK-MES-1 cells and the cells transfected with the empty pcDNA3.1 plasmid, the ARHI-transfected cells displayed significantly reduced growth rates and decreased viability (P < 0.05). The ARHI-transfected cells also displayed a significantly higher percentage of cells in G1 phase (P < 0.05) and a lower percentage of cells in S phase (P < 0.05); a higher percentage of apoptosis (P < 0.05); and finally, a notable reduction in the basement membrane-penetration rate in the Transwell invasion assay (P < 0.05). Furthermore, it was determined that ARHI is capable of inhibiting the expression of cyclin D1, MMP-1, and MMP-2; however, ARHI promotes the expression of both p27(KIP1) and DAPK1 in SK-MES-1 cells. In conclusion, overexpression of ARHI gene might be associated with the inhibition of lung cancer cell growth, proliferation and invasion, and the promotion of apoptosis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23247805     DOI: 10.1007/s11033-012-2353-x

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  24 in total

1.  Reexpression of ARHI inhibits tumor growth and angiogenesis and impairs the mTOR/VEGF pathway in hepatocellular carcinoma.

Authors:  Xiaohai Zhao; Jinfeng Li; Jianxin Zhuo; Liuxin Cai
Journal:  Biochem Biophys Res Commun       Date:  2010-11-17       Impact factor: 3.575

2.  New molecular targeted therapies for advanced non-small-cell lung cancer.

Authors:  Míriam Méndez; Ana Custodio; Mariano Provencio
Journal:  J Thorac Dis       Date:  2011-03       Impact factor: 2.895

3.  The expression and clinical significance of GTP-binding RAS-like 3 (ARHI) and microRNA 221 and 222 in prostate cancer.

Authors:  D Lin; F Cui; Q Bu; C Yan
Journal:  J Int Med Res       Date:  2011       Impact factor: 1.671

4.  Tissue Factor/ FVIIa prevents the extrinsic pathway of apoptosis by regulation of the tumor suppressor Death-Associated Protein Kinase 1 (DAPK1).

Authors:  M Aberg; M Johnell; M Wickström; A Siegbahn
Journal:  Thromb Res       Date:  2010-12-17       Impact factor: 3.944

5.  Expression of matrix metalloproteinases 1, 2, 9 and their tissue inhibitors in stage II non-small cell lung cancer: implications for MMP inhibition therapy.

Authors:  S C Pritchard; M C Nicolson; C Lloret; J A McKay; V G Ross; K M Kerr; G I Murray; H L McLeod
Journal:  Oncol Rep       Date:  2001 Mar-Apr       Impact factor: 3.906

Review 6.  Angiogenesis in cancer: Anti-VEGF escape mechanisms.

Authors:  Gerald W Prager; Marina Poettler; Matthias Unseld; Christoph C Zielinski
Journal:  Transl Lung Cancer Res       Date:  2012-03

7.  Methylation discriminators in NSCLC identified by a microarray based approach.

Authors:  J K Field; T Liloglou; S Warrak; M Burger; E Becker; K Berlin; I Nimmrich; S Maier
Journal:  Int J Oncol       Date:  2005-07       Impact factor: 5.650

8.  Heparin based nanoparticles for cancer targeting and noninvasive imaging.

Authors:  Md Nurunnabi; Zehedina Khatun; Woo-Choon Moon; Gibaek Lee; Yong-Kyu Lee
Journal:  Quant Imaging Med Surg       Date:  2012-09

9.  Expression of the tumor suppressor gene ARHI in epithelial ovarian cancer is associated with increased expression of p21WAF1/CIP1 and prolonged progression-free survival.

Authors:  Daniel G Rosen; Lin Wang; Ajay N Jain; Karen H Lu; Robert Z Luo; Yinhua Yu; Jinsong Liu; Robert C Bast
Journal:  Clin Cancer Res       Date:  2004-10-01       Impact factor: 12.531

10.  The matrix metalloproteinase/tissue inhibitor of matrix metalloproteinase profile in colorectal polyp cancers.

Authors:  Natalie Jeffery; Mairi H McLean; Emad M El-Omar; Graeme I Murray
Journal:  Histopathology       Date:  2009-06       Impact factor: 5.087

View more
  11 in total

1.  Over-expression of ARHI decreases tumor growth, migration, and invasion in human glioma.

Authors:  Jing Chen; Songsheng Shi; Weizhong Yang; Chunmei Chen
Journal:  Med Oncol       Date:  2014-01-24       Impact factor: 3.064

2.  ARHI (DIRAS3) induces autophagy in ovarian cancer cells by downregulating the epidermal growth factor receptor, inhibiting PI3K and Ras/MAP signaling and activating the FOXo3a-mediated induction of Rab7.

Authors:  Z Lu; H Yang; M N Sutton; M Yang; C H Clarke; W S-L Liao; R C Bast
Journal:  Cell Death Differ       Date:  2014-04-25       Impact factor: 15.828

3.  The role of aplysia ras homolog I in colon cancer cell invasion and adhesion.

Authors:  Jun Ouyang; Xiaohui Pan; Zecheng Hu
Journal:  Exp Ther Med       Date:  2017-09-18       Impact factor: 2.447

4.  DIRAS3 regulates the autophagosome initiation complex in dormant ovarian cancer cells.

Authors:  Zhen Lu; Maria T Baquero; Hailing Yang; Maojie Yang; Albert S Reger; Choel Kim; Douglas A Levine; Charlotte H Clarke; Warren S-L Liao; Robert C Bast
Journal:  Autophagy       Date:  2014-06       Impact factor: 16.016

5.  DIRAS3 (ARHI) Blocks RAS/MAPK Signaling by Binding Directly to RAS and Disrupting RAS Clusters.

Authors:  Margie N Sutton; Zhen Lu; Yao-Cheng Li; Yong Zhou; Tao Huang; Albert S Reger; Amy M Hurwitz; Timothy Palzkill; Craig Logsdon; Xiaowen Liang; Joe W Gray; Xiaolin Nan; John Hancock; Geoffrey M Wahl; Robert C Bast
Journal:  Cell Rep       Date:  2019-12-10       Impact factor: 9.423

6.  Expression and epigenetic regulation of angiogenesis-related factors during dormancy and recurrent growth of ovarian carcinoma.

Authors:  Tianjiao Lyu; Nan Jia; Jieyu Wang; Xiaohui Yan; Yinhua Yu; Zhen Lu; Robert C Bast; Keqin Hua; Weiwei Feng
Journal:  Epigenetics       Date:  2013-10-17       Impact factor: 4.528

7.  Loss of ARHI expression in colon cancer and its clinical significance.

Authors:  Wei Wang; Lili Chen; Qun Tang; Yonggang Fan; Xiaoru Zhang; Jingming Zhai
Journal:  Contemp Oncol (Pozn)       Date:  2014-11-05

8.  The expression of aplysia ras homolog I (ARHI) and its inhibitory effect on cell biological behavior in esophageal squamous cell carcinoma.

Authors:  Yuqiang Mao; Yun Han; Wenjun Shi
Journal:  Onco Targets Ther       Date:  2017-02-27       Impact factor: 4.147

Review 9.  RAS Dimers: The Novice Couple at the RAS-ERK Pathway Ball.

Authors:  Ana Herrero; Piero Crespo
Journal:  Genes (Basel)       Date:  2021-09-30       Impact factor: 4.096

10.  Transcriptional silencing of long noncoding RNA GNG12-AS1 uncouples its transcriptional and product-related functions.

Authors:  Lovorka Stojic; Malwina Niemczyk; Arturo Orjalo; Yoko Ito; Anna Elisabeth Maria Ruijter; Santiago Uribe-Lewis; Nimesh Joseph; Stephen Weston; Suraj Menon; Duncan T Odom; John Rinn; Fanni Gergely; Adele Murrell
Journal:  Nat Commun       Date:  2016-02-02       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.